KALA BIO (KALA) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
KALA BIO is the larger company by market cap ($5.7 million vs $137,318), about 41.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KALA | MDCX |
|---|---|---|
| Share price | $0.2927 | $0.0916 |
| Market cap | $5.66M | $137.32K |
| 1-day change | -1.31% | -10.11% |
| YTD return | — | -93.34% |
| 1-year return | — | -95.86% |
| EPS (TTM) | $-10.71 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $95.50 | $139.00 |
| 52-week low | $0.286 | $0.084 |
| Distance from 52-week high | -99.69% | -99.93% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +4812.66% |
| Average volume | 1.46M | 92.96K |
| Shares outstanding | 19.34M | 1.50M |
| Employees | 6 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KALA BIO is about 41.2 times larger than Medicus Pharma by market value ($5.66M vs $137.32K).
About KALA BIO
KALA stock →KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
KALA vs MDCX FAQ
Which is bigger, KALA BIO or Medicus Pharma?
KALA BIO (KALA) is larger, with a market capitalization of $5.66M compared with $137.32K for Medicus Pharma (MDCX).
Are KALA BIO and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.